{"schema_version":"secwatch.filing_event.v1","accession":"0001701541-23-000039","form_type":"8-K","ticker":"BDTX","cik":"0001701541","company_name":"Black Diamond Therapeutics, Inc.","filed_at":"2023-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.905344+00:00","generated_at":"2026-06-11T14:46:21.591630+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Black Diamond Therapeutics Q2 net loss $20M; cash $89.5M; BDTX-1535 shows initial clinical activity","bullets":["Net loss $20.0M for Q2 2023 vs $23.2M for Q2 2022; R&D expenses $13.2M down from $16.2M.","Cash, equivalents & investments $89.5M as of June 30, 2023; plus $75M gross from July follow-on offering extends runway into H1 2025.","BDTX-1535 Phase 1 dose-escalation showed confirmed partial responses in 5 of 12 evaluable NSCLC patients; expansion cohorts initiated July 2023.","Phase 1 trial for BDTX-4933 (BRAF/RAS inhibitor) initiated in Q2 2023; GBM dose-escalation update expected Q4 2023.","FDA meeting planned in Q4 2023 to discuss accelerated approval pathway for BDTX-1535 in NSCLC."],"urls":{"canonical":"https://secwatch.observer/filing/0001701541-23-000039","json":"https://secwatch.observer/filing/0001701541-23-000039.json","markdown":"https://secwatch.observer/filing/0001701541-23-000039.md","text":"https://secwatch.observer/filing/0001701541-23-000039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701541/000170154123000039/0001701541-23-000039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701541/000170154123000039/bdtx-20230811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T14:46:21.591630+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d299fb96b8b457ec06b3b24d4acca835733bb527","claim":"Black Diamond Therapeutics, Inc. reported financial results for the second quarter ended June 30, 2023.","evidence_excerpt":"Black Diamond Therapeutics, Inc. announced its financial results for the second quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701541/000170154123000039/0001701541-23-000039-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}